Dechra Veterinary Products Limited (“Dechra”)
‘Partner In Care’ Scheme

These terms and conditions relate to the ‘Partner In Care’ Scheme (the “Scheme”) and any Practice joining the Scheme is deemed to have accepted and be bound by them.

Definitions:
“Eligible Practice” means a Practice that has diagnosed a New Patient during the Scheme Period.
“Eligible Products” means those of Dechra and/or its Group companies’ veterinary products which form part of the Scheme from time to time, as detailed in the Scheme Marketing Materials.
“New Patient” a patient of the Practice diagnosed during the Scheme Period by a veterinary professional at the Practice as having the Relevant Disease and that is prescribed the applicable Eligible Product as the recommended course of treatment by the Practice.
“Practice” means an independent veterinary practice in the United Kingdom that has registered for the Scheme.
“Relevant Disease” means a disease which is treated by an Eligible Product, as set out on an Eligible Product-by-Eligible Product basis in the Scheme Marketing Materials.
“Scheme Marketing Materials” means the marketing materials which accompany the Scheme, as set out at Partner In Care and updated from time to time.
“Scheme Start Date” means 14 July 2025.

1. Basis of the Scheme

The participation by a Practice in the Scheme must never lead to higher costs for pet owners, reduce the quality of services to pet owners, compromise veterinary care for animals, lead to an increase of the prescription and/or use of veterinary medical products by the Practice, and each individual veterinarian will ultimately make the final decision on which veterinary medicinal product to use or prescribe, with such choice being made on the basis of clinical need.

2. New Patients and free of charge product

For each New Patient, the Eligible Practice will be entitled to one free of charge pack of the relevant Eligible Product (“FOC Product”). Dechra shall ensure that the FOC Product is provided to the Eligible Practice free of charge by the relevant wholesaler, subject to any shipping and delivery charges the wholesaler may impose on the Practice and which the Practice shall be responsible to pay.

3. Collaboration Activities

The Practice agrees to work with Dechra sales, technical and marketing staff to:

1. understand and develop opportunities for participation in the Scheme;
2. develop clinical understanding of Cushing’s disease within its Practice;
3. increase dog-owner awareness of Cushing’s disease, its signs and symptoms; and
4. support dog-owners through the diagnostic and treatment process.

 

4. ​When will the FOC Product be provided

The FOC Product will be provided by the relevant wholesaler at the instruction of Dechra on such dates and in such volume and dosages as agreed between the Eligible Practice and the relevant Dechra territory sales manager.

5. FOC Product is subject to availability

The provision of FOC Product shall be subject always to stock availability at the wholesaler and/or at Dechra. Dechra reserves the right to refuse supply of the FOC Product in its sole discretion.

6. Duration of the Scheme

The Scheme shall commence on the Scheme Start Date and shall run until terminated by Dechra (in its sole discretion) (the “Scheme Period”). The Scheme shall only be valid for New Patients prescribed an Eligible Product during the Scheme Period. Any patient diagnosed with a Relevant Disease after the Scheme Period shall not be considered a New Patient and no FOC Product shall be supplied in respect of that patient. Dechra reserves the right to withdraw, terminate or alter the terms of the Scheme at any time at its absolute discretion.

7. Eligibility criteria for receiving FOC Product

In order for the Eligible Practice to remain eligible for the Scheme, the Practice must retain its independent status (i.e. non corporate ownership) until after the FOC Product has been delivered to the Practice. Where a Practice is also a member of a buying group and, by virtue of that membership, is entitled to receive a rebate, discount or other promotional offer related to its purchases of the relevant Eligible Product, it shall not be eligible to participate in the Scheme and shall not be entitled to any FOC Product.

8. New Patient Enrolment Records

An Eligible Practice must record the New Patient details on the Partner In Care Registration Form (provided by Dechra from time to time) as accurately as possible in order for the FOC Product to be provided. The Practice must not falsify any registrations in order to fraudulently claim FOC Product. Dechra reserves the right to challenge or query any registration forms completed and refuse to supply FOC Product in circumstances where it suspects the Practice has submitted any registrations fraudulently or erroneously. Dechra shall be entitled to request evidence of and the records relating to New Patient enrolments at any time.

9. General

 

1. These Terms and Conditions relate purely to the Scheme and have no bearing on a Practice’s relationship with the relevant wholesalers. No Dechra products (including Eligible Products) will be purchased by the Practice from Dechra under the Scheme and the Practice will continue to purchase products from wholesalers in accordance with the terms of the agreement(s) in place between the Practice and the wholesalers. No exclusive rights are granted by Dechra to the Practice pursuant to the Scheme and these Terms and Conditions.
2. The Practice and Dechra shall comply with all applicable laws (including all applicable anti-bribery and anti-corruption laws and all applicable data protection laws) and shall procure that their employees, officers and directors do not take any actions or make any omissions that would cause either party to be in violation of any applicable laws.
3. The Practice agrees that it will not do anything which would bring the name, trademarks, intellectual property or goodwill of Dechra into disrepute in any manner whatsoever.
4. The Practice may not assign or transfer its rights and/or obligations under the Scheme to any other party.
5. Neither Dechra nor the Practice intend that any of its terms will be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by any person not a party to it.
6. Nothing in these Terms and Conditions is intended to create a partnership, joint venture, joint undertaking or legal relationship of any kind that would impose liability upon one party for the act or omission of the other party, or to authorise either party to act as agent for the other.
7. Failure or delay by Dechra or the Practice in enforcing or partially enforcing any provision of these Terms and Conditions shall not be construed as a waiver of any of its rights thereunder.
8. No waiver by a party of any breach of these Terms and Conditions by the other party shall be considered as a waiver of any subsequent breach of the same or any other provision.
9. If any provision of Terms and Conditions is held by any competent authority to be invalid or unenforceable in whole or in part, the validity of the other provisions of these Terms and Conditions and the remainder of the provision in question shall not be affected thereby.
10. These Terms and Conditions and any dispute or claim arising out of or in connection with it shall be governed by English Law and the parties hereby agree to submit to the exclusive jurisdiction of the courts of England and Wales.

Dechra Veterinary Products Limited (“Dechra”)

Pergocoat Advantage Scheme Terms and Conditions

These terms and conditions relate to the Pergocoat Advantage Scheme (the “Scheme”) and any Practice joining the Scheme is deemed to have accepted and be bound by them.

Definitions:

“Eligible Practice” means a Practice that has administered a dose of the Product to a New Patient during the Scheme Period.

“New Patient” a patient of the Practice that has not been administered with a dose of the Product in the twelve months prior to the start of the Scheme Period.  

“Practice” means an independent veterinary practice in the United Kingdom that has registered for the Scheme.

“Product” means the film-coated tablets for the treatment of pituitary pars intermedia dysfunction (‘PPID’) in horses, marketed by Dechra in the UK under the brand name “Pergocoat”.

“Scheme Period” means the period starting 1st July 2024 and ending 30th June 2026.

Basis of the Scheme

The participation by a Practice in the Scheme must never lead to higher costs for pet owners, reduce the quality of services to pet owners, compromise veterinary care for animals, lead to an increase of the prescription and/or use of veterinary medical products by the Practice, and each individual veterinarian will ultimately make the final decision on which veterinary medicinal product to use or prescribe, with such choice being made on the basis of clinical need.

New Patients and free of charge product

For each New Patient administered with a dose of the Product by the Eligible Practice during the Scheme Period, the Eligible Practice will be entitled to two months’ worth of the Product to treat one New Patient (“FOC Product”) to be dispensed by the veterinary professional to the New Patient.  Dechra shall ensure that the FOC Product is provided to the Eligible Practice free of charge by the relevant wholesaler, subject to any shipping and delivery charges the wholesaler may impose on the Practice and which the Practice shall be responsible to pay.

Collaboration Activities

The Practice agrees to work with Dechra sales, technical and marketing staff to:

understand and develop opportunities for participation in the Scheme;
develop clinical understanding of PPID within its Practice;
increase horse-owner awareness of PPID, its signs and symptoms;
support horse-owners through the diagnostic and treatment process.

When will the FOC Product be provided 

The FOC Product will be provided by the relevant wholesaler at the instruction of Dechra on such dates and in such volume and dosages as agreed between the Eligible Practice and the relevant Dechra territory sales manager.

FOC Product is subject to availability

The provision of FOC Product shall be subject always to stock availability at the wholesaler and/or at Dechra.  Dechra reserves the right to refuse supply of the FOC Product in circumstances where there are stock shortages in the marketplace.  In the event the FOC Product is out of stock, and such out of stock situation persists beyond the end of the Scheme Period, the Scheme shall lapse and Dechra shall not be obliged to provide the FOC Product to the Eligible Practice.

Duration of the Scheme

The Scheme shall only be valid for New Patients administered with a dose of the Product during the Scheme Period and shall expire at the end of the Scheme Period.  Any patient administered with a dose of the Product after the end of the Scheme Period shall not be considered a New Patient and no FOC Product shall be supplied in respect of that patient. Dechra reserves the right to withdraw, terminate or alter the terms of the Scheme at any time throughout the Scheme Period at its absolute discretion.   The Practice acknowledges that the Scheme and FOC Product is subject to availability and may be subject to change at any time.

Eligibility criteria for receiving FOC Product

In order for the Eligible Practice to remain eligible for the Scheme, the Practice must retain its independent status (i.e. non corporate ownership) until after the FOC Product has been delivered to the Practice. Where a Practice is also a member of a buying group and, by virtue of that membership, is entitled to receive a rebate, discount or other promotional offer related to its purchases of the Product, it shall not be eligible to participate in the Scheme and shall not be entitled to any FOC Product.

New Patient Enrolment Records

An Eligible Practice must record the New Patient details on the Pergocoat Advantage New Patient Registration Form (provided by Dechra from time to time) as accurately as possible in order for the FOC Product to be provided.  The Practice must not falsify any registrations in order to fraudulently claim FOC Product.  Dechra reserves the right to challenge or query any registration forms completed and refuse to supply FOC Product in circumstances where it suspects the Practice has submitted any registrations fraudulently or erroneously.  Dechra shall be entitled to request evidence of and the records relating to New Patient enrolments at any time

General

These Terms and Conditions relate purely to the Scheme and have no bearing on a Practice’s relationship with the relevant wholesalers.  No Dechra products (including the Product) will be purchased by the Practice from Dechra under the Scheme and the Practice will continue to purchase products (including the Product) from wholesalers in accordance with the terms of the agreement(s) in place between the Practice and the wholesalers.  No exclusive rights are granted by Dechra to the Practice pursuant to the Scheme and these Terms and Conditions. 

 

The Practice and Dechra shall comply with all applicable laws (including all applicable anti-bribery and anti-corruption laws and all applicable data protection laws) and shall procure that their employees, officers and directors do not take any actions or make any omissions that would cause either party to be in violation of any applicable laws. 

 

The Practice agrees that it will not do anything which would bring the name, trademarks, intellectual property or goodwill of Dechra into disrepute in any manner whatsoever.

 

The Practice may not assign or transfer its rights and/or obligations under the Scheme to any other party.

 

Neither Dechra nor the Practice intend that any of its terms will be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by any person not a party to it.

 

Nothing in these Terms and Conditions is intended to create a partnership, joint venture, joint undertaking or legal relationship of any kind that would impose liability upon one party for the act or omission of the other party, or to authorise either party to act as agent for the other.

 

Failure or delay by Dechra or the Practice in enforcing or partially enforcing any provision of these Terms and Conditions shall not be construed as a waiver of any of its rights thereunder.

 

No waiver by a party of any breach of these Terms and Conditions by the other party shall be considered as a waiver of any subsequent breach of the same or any other provision.

 

If any provision of Terms and Conditions is held by any competent authority to be invalid or unenforceable in whole or in part, the validity of the other provisions of these Terms and Conditions and the remainder of the provision in question shall not be affected thereby.

 

These Terms and Conditions and any dispute or claim arising out of or in connection with it shall be governed by English Law and the parties hereby agree to submit to the exclusive jurisdiction of the courts of England and Wales.

Dechra Veterinary Products Limited (“Dechra”)

Strangvac^® Vaccination Amnesty Scheme Terms and Conditions

These terms and conditions relate to the Strangvac^® Vaccination Amnesty Scheme (the “Scheme”) and any Practice joining the Scheme is deemed to have accepted and be bound by them.

Definitions:

“Campaign Month” means a calendar month during the Scheme Year in which the Practice will run a marketing campaign to increase awareness of the respiratory disease “strangles” in horses, as such month is agreed between the Practice and Dechra in advance.

“Eligible Practice” means a Practice that has Vaccinated a New Patient during the Scheme Year.

“New Patient” means a patient of the Practice that has not received a dose of the Product in the twelve months prior to the start of the Scheme Year.

“Practice” means an independent veterinary practice in the United Kingdom or Republic of Ireland that has registered for the Scheme.

“Product” means the veterinary medicinal suspension for injection of horses, marketed by Dechra in the UK and Republic of Ireland under the registered trademark “Strangvac”.

“Scheme Year” means the period starting 1 June 2024 and ending on 31 May 2025.

“Vaccinated” means that a New patient has been administered two doses of the Product during the Scheme Year, with the first dose being administered during the Campaign Month.

1. Basis of the Scheme

The participation by a Practice in the Scheme must never lead to higher costs for pet owners, reduce the quality of services to pet owners, compromise veterinary care for animals, lead to an increase of the prescription and/or use of veterinary medical products by the Practice, and each individual veterinarian will ultimately make the final decision on which veterinary medicinal product to use or prescribe, with such choice being made on the basis of clinical need.

2. New Patients and free of charge product

For each New Patient that is Vaccinated by the Eligible Practice, the Eligible Practice will be entitled to a free dose of the Product to treat its patients (“FOC Product”), such FOC Product to be dispensed by the veterinary professional.  Dechra shall ensure that the FOC Product is provided to the Eligible Practice free of charge by the relevant wholesaler, subject to any shipping and delivery charges the wholesaler may impose on the Practice and which the Practice shall be responsible to pay.

3. Collaboration Activities

The Practice agrees to work with Dechra sales, technical and marketing staff to:

1. understand and develop opportunities for participation in the Scheme;
2. develop clinical understanding of strangles disease within its Practice;
3. increase horse-owner awareness of strangles disease, its signs and symptoms,  including (but not limited to) by way of social media posts and other communications to horse owners during the Campaign Month;
4. support horse-owners through the diagnostic and treatment process.

4. When will the FOC Product be provided 

The FOC Product will be provided by the relevant wholesaler at the instruction of Dechra on such dates and in such volume and dosages as agreed between the Eligible Practice and the relevant Dechra territory sales manager.

5. FOC Product is subject to availability

The provision of FOC Product shall be subject always to stock availability at the wholesaler and/or at Dechra.  Dechra reserves the right to refuse supply of the FOC Product in circumstances where there are stock shortages in the marketplace.  In the event the Product is out of stock, and such out of stock situation persists beyond the end of the Scheme Year, the Scheme shall lapse and Dechra shall not be obliged to provide the FOC Product to the Eligible Practice.

6. Duration of the Scheme

The Scheme shall only be valid for New Patients Vaccinated during the Scheme Year and shall expire on 31 May 2025.  Any patient administered with its first or second dose of the Product after the end of the Scheme Year shall not be considered a Vaccinated New Patient and no FOC Product shall be supplied in respect of that patient.  Dechra reserves the right to withdraw, terminate or alter the terms of the Scheme at any time throughout the Scheme Year at its absolute discretion.  The Practice acknowledges that the Scheme and FOC Product is subject to availability and may be subject to change at any time.

7. Eligibility criteria for receiving FOC Product

In order for the Eligible Practice to remain eligible for the Scheme, the Practice must retain its independent status (i.e. non corporate ownership) until after the FOC Product has been delivered to the Practice. Where a Practice is also a member of a buying group and, by virtue of that membership, is entitled to receive a rebate, discount or other promotional offer related to its purchases of the Product, it shall not be eligible to participate in the Scheme and shall not be entitled to any FOC Product.

8. New Patient Enrolment Records

An Eligible Practice must record the New Patient details on the Strangvac® Vaccination Amnesty New Patient Registration Form (provided by Dechra from time to time) as accurately as possible in order for the FOC Product to be provided.  The Practice must not falsify any registrations in order to fraudulently claim FOC Product.  Dechra reserves the right to challenge or query any registration forms completed and refuse to supply FOC Product in circumstances where it suspects the Practice has submitted any registrations fraudulently or erroneously.  Dechra shall be entitled to request evidence of and the records relating to New Patient enrolments at any time.

9. General

1. These Terms and Conditions relate purely to the Scheme and have no bearing on a Practice’s relationship with the relevant wholesalers.  No Dechra products (including the Product) will be purchased by the Practice from Dechra under the Scheme and the Practice will continue to purchase products (including the Product) from wholesalers in accordance with the terms of the agreement(s) in place between the Practice and the wholesalers.  No exclusive rights are granted by Dechra to the Practice pursuant to the Scheme and these Terms and Conditions. 
2. The Practice and Dechra shall comply with all applicable laws (including all applicable anti-bribery and anti-corruption laws and all applicable data protection laws) and shall procure that their employees, officers and directors do not take any actions or make any omissions that would cause either party to be in violation of any applicable laws. 
3. The Practice agrees that it will not do anything which would bring the name, trademarks, intellectual property or goodwill of Dechra or its licensors (as applicable) into disrepute in any manner whatsoever.
4. The Practice may not assign or transfer its rights and/or obligations under the Scheme to any other party.
5. Neither Dechra nor the Practice intend that any of its terms will be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by any person not a party to it.
6. Nothing in these Terms and Conditions is intended to create a partnership, joint venture, joint undertaking or legal relationship of any kind that would impose liability upon one party for the act or omission of the other party, or to authorise either party to act as agent for the other.
7. Failure or delay by Dechra or the Practice in enforcing or partially enforcing any provision of these Terms and Conditions shall not be construed as a waiver of any of its rights thereunder.
8. No waiver by a party of any breach of these Terms and Conditions by the other party shall be considered as a waiver of any subsequent breach of the same or any other provision.
9. If any provision of Terms and Conditions is held by any competent authority to be invalid or unenforceable in whole or in part, the validity of the other provisions of these Terms and Conditions and the remainder of the provision in question shall not be affected thereby.
10. These Terms and Conditions and any dispute or claim arising out of or in connection with it shall be governed by English Law and the parties hereby agree to submit to the exclusive jurisdiction of the courts of England and Wales.

Dechra Veterinary Products Limited (“Dechra”)

Strangvac^® Vaccination Amnesty Scheme Terms and Conditions for VetPartners clinics

These terms and conditions relate to the Strangvac^® Vaccination Amnesty Scheme (the “Scheme”) and any Practice joining the Scheme is deemed to have accepted and be bound by them.

Definitions:

“Campaign Month” means a calendar month during the Scheme Year in which the Practice will run a marketing campaign to increase awareness of the respiratory disease “strangles” in horses, as such month is agreed between the Practice and Dechra in advance.

“Eligible Practice” means a Practice that has Vaccinated a New Patient during the Scheme Year.

“New Patient” means a patient of the Practice that has not received a dose of the Product in the twelve months prior to the start of the Scheme Year.

“Practice” means an animal hospital or clinic that: (i) is based in the United Kingdom; (ii) is owned by VetPartners; and (iii) has registered for the Scheme.

“Product” means the veterinary medicinal suspension for injection of horses, marketed by Dechra in the UK and Republic of Ireland under the registered trademark “Strangvac”.

“Scheme Year” means the period starting 01/02/2025 and ending on 31/01/2026.

“Vaccinated” means that a New Patient has been administered two doses of the Product during the Scheme Year, with the first dose being administered during the Campaign Month.

“VetPartners” means VetPartners Limited, a company registered in England and Wales under Company number 10026837, whose registered office is at Spitfire House, Aviator Court, York, UK.

1. Basis of the Scheme

The participation by a Practice in the Scheme must never lead to higher costs for pet owners, reduce the quality of services to pet owners, compromise veterinary care for animals, lead to an increase of the prescription and/or use of veterinary medical products by the Practice, and each individual veterinarian will ultimately make the final decision on which veterinary medicinal product to use or prescribe, with such choice being made on the basis of clinical need.

2. New Patients and free of charge product

For each New Patient that is Vaccinated by the Eligible Practice, the Eligible Practice will be entitled to a free dose of the Product to treat its patients (“FOC Product”), such FOC Product to be dispensed by the veterinary professional.  Dechra shall ensure that the FOC Product is provided to the Eligible Practice free of charge by the relevant wholesaler, subject to any shipping and delivery charges the wholesaler may impose on the Practice and which the Practice shall be responsible to pay.

3. Collaboration Activities

The Practice agrees to work with Dechra sales, technical and marketing staff to:

1. understand and develop opportunities for participation in the Scheme;
2. develop clinical understanding of strangles disease within its Practice;
3. increase horse-owner awareness of strangles disease, its signs and symptoms, including (but not limited to) by way of social media posts and other communications to horse owners during the Campaign Month;
4. support horse-owners through the diagnostic and treatment process.

4. When will the FOC Product be provided 

The FOC Product will be provided by the relevant wholesaler at the instruction of Dechra on such dates and in such volume and dosages as agreed between the Eligible Practice and the relevant Dechra territory sales manager.

5. FOC Product is subject to availability

The provision of FOC Product shall be subject always to stock availability at the wholesaler and/or at Dechra.  Dechra reserves the right to refuse supply of the FOC Product in circumstances where there are stock shortages in the marketplace.  In the event the Product is out of stock, and such out of stock situation persists beyond the end of the Scheme Year, the Scheme shall lapse and Dechra shall not be obliged to provide the FOC Product to the Eligible Practice.

6. Duration of the Scheme

The Scheme shall only be valid for New Patients that are Vaccinated during the Scheme Year and shall expire on 31/01/2026.  Any patient administered with its first or second dose of the Product after the end of the Scheme Year shall not be considered a Vaccinated New Patient and no FOC Product shall be supplied in respect of that patient.  Dechra reserves the right to withdraw, terminate or alter the terms of the Scheme at any time throughout the Scheme Year at its absolute discretion.  The Practice acknowledges that the Scheme and FOC Product is subject to availability and may be subject to change at any time.

7. Eligibility criteria for receiving FOC Product

In order for the Eligible Practice to remain eligible for the Scheme, the Practice must retain its status as part of VetPartners’ group of companies until after the FOC Product has been delivered to the Practice.

8. New Patient Enrolment Records

An Eligible Practice must record the New Patient details on the Strangvac® Vaccination Amnesty New Patient Registration Form (provided by Dechra from time to time) as accurately as possible in order for the FOC Product to be provided.  The Practice must not falsify any registrations in order to fraudulently claim FOC Product.  Dechra reserves the right to challenge or query any registration forms completed and refuse to supply FOC Product in circumstances where it suspects the Practice has submitted any registrations fraudulently or erroneously.  Dechra shall be entitled to request evidence of and the records relating to New Patient enrolments at any time.

9. General

1. These Terms and Conditions relate purely to the Scheme and have no bearing on a Practice’s or VetPartners’ relationship with the relevant wholesalers.  No Dechra products (including the Product) will be purchased by the Practice from Dechra under the Scheme and the Practice will continue to purchase products (including the Product) from wholesalers in accordance with the terms of the agreement(s) in place between the Practice and the wholesalers.  No exclusive rights are granted by Dechra to the Practice pursuant to the Scheme and these Terms and Conditions. 
2. The Practice and Dechra shall comply with all applicable laws (including all applicable anti-bribery and anti-corruption laws and all applicable data protection laws) and shall procure that their employees, officers and directors do not take any actions or make any omissions that would cause either party to be in violation of any applicable laws. 
3. The Practice agrees that it will not do anything which would bring the name, trademarks, intellectual property or goodwill of Dechra or its licensors (as applicable) into disrepute in any manner whatsoever.
4. The Practice may not assign or transfer its rights and/or obligations under the Scheme to any other party.
5. Neither Dechra nor the Practice intend that any of its terms will be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by any person not a party to it.
6. Nothing in these Terms and Conditions is intended to create a partnership, joint venture, joint undertaking or legal relationship of any kind that would impose liability upon one party for the act or omission of the other party, or to authorise either party to act as agent for the other.
7. Failure or delay by Dechra or the Practice in enforcing or partially enforcing any provision of these Terms and Conditions shall not be construed as a waiver of any of its rights thereunder.
8. No waiver by a party of any breach of these Terms and Conditions by the other party shall be considered as a waiver of any subsequent breach of the same or any other provision.
9. If any provision of Terms and Conditions is held by any competent authority to be invalid or unenforceable in whole or in part, the validity of the other provisions of these Terms and Conditions and the remainder of the provision in question shall not be affected thereby.
10. These Terms and Conditions and any dispute or claim arising out of or in connection with it shall be governed by English Law and the parties hereby agree to submit to the exclusive jurisdiction of the courts of England and Wales.